Science: Mechanism of Action

The evidence provided does not contain detailed mechanistic studies explaining how semaglutide works at the molecular or physiological level. The available studies focus primarily on clinical effectiveness, safety profiles, and real-world usage patterns rather than fundamental mechanisms.

From the limited mechanistic information available in the evidence:

GLP-1 Receptor Agonism: Semaglutide functions as a glucagon-like peptide-1 (GLP-1) receptor agonist, as referenced in several of the clinical studies. One study specifically examines "Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists" and another investigates "Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy."

Clinical Trial Evidence: A completed Phase 1 study (NCT05435677) examined "how insulin icodec and semaglutide work in the body" when given alone or together, and another completed Phase 1 trial (NCT05784402) investigated semaglutide blood levels with different oral formulations, but the mechanistic details from these studies are not provided in the evidence.

Evidence Limitations: The current evidence set lacks foundational research papers that would typically describe semaglutide's molecular mechanism of action, including details about GLP-1 receptor binding, intracellular signaling pathways, effects on insulin secretion, glucagon suppression, gastric emptying, or appetite regulation at the hypothalamic level.

To fully understand semaglutide's mechanism of action, additional evidence from basic science and pharmacology studies would be needed beyond what is currently available in this evidence set.

Note: This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers for personalized treatment decisions.